BioPharma Dive5h
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Medicare’s 2025 Drug Negotiation List Includes Ozempic and Wegovy
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
NL Times9h
European Medicines Agency to investigate link between Ozempic and rare eye disorder
The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...
Medicare Will Pay Less for Ozempic and Wegovy in 2027. The Price-Negotiation List Is Out.
Medicare will soon start paying lower prices for Novo Nordisk’s weight- loss drug Wegovy and its Type 2 diabetes treatment ...
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Ozempic could get cheaper as Medicare eyes drug price negotiations — and Novo Nordisk stock slips
The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...
Channel 300011h
Ozempic, Wegovy and other drugs are among 15 selected for Medicare's price negotiations
The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating ...